EXEL
Exelixis
Biological Products, (No Diagnostic Substances) · Health Care
$72.31+3.11%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Why no score
Fewer than four score groups have enough coverage.
- Balance sheet. Coverage is 35%, under the 70% line. Net debt / EBITDA: Not in the filing or the stored price history. Interest coverage: Not in the filing or the stored price history. Altman Z-double-prime: Not in the filing or the stored price history.
- Valuation. Coverage is 67%, under the 70% line. Earnings yield: Not in the filing or the stored price history. EV/Sales vs sector: Not in the filing or the stored price history.
- Momentum and quality. Coverage is 63%, under the 70% line. Piotroski F-score: Needs the filing fields for the nine accounting checks. Beneish M-score: Needs the filing fields for the eight-variable screen.
In plain English
- Exelixis operates in Biological Products, (No Diagnostic Substances).
- No profile score is shown.
- The score card lists which groups fell short.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2026-01-02. Latest quarter ended 2026-10-02. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
SEC EDGAR companyfacts, fetched 2026-11-01.